A NEW

drug, anacetrapib, that raises ‘good’ HDL cholesterol and lowers ‘ bad’ LDL, reduces risk of death in people who don’t respond to statins. A four-year study with 30,000 patients showed promising results, according to initial analysis by maker Merck. It blocks a protein that helps to transport cholesterol.